A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
This open-label, multicenter, Phase I, dose-escalating study will evaluate the safety and
tolerability, pharmacokinetics, pharmacodynamics and efficacy of GDC-0084 in patients with
progressive or recurrent high-grade glioma. Stage 1 is the dose escalation part of the study.
Stage 2, patients will receive GDC-0084 at a recommended dose for future studies.